ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SABS SAB Biotherapeutics Inc

4.03
0.01 (0.25%)
After Hours
Last Updated: 07:16:11
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
SAB Biotherapeutics Inc SABS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.01 0.25% 4.03 07:16:11
Open Price Low Price High Price Close Price Previous Close
4.00 4.00 4.1002 4.03 4.02
more quote information »

Recent News

Date Time Source Heading
16/4/202421:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202421:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202422:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202422:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
26/3/202401:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
09/3/202408:30EDGAR2Form 8-K - Current report
24/2/202408:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202408:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202400:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
09/2/202400:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202423:53EDGAR2Form 8-K - Current report
02/2/202423:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
27/1/202408:15EDGAR2Form 8-K - Current report
27/1/202408:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/1/202409:00EDGAR2Form 8-K - Current report
24/1/202409:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
20/1/202408:21EDGAR2Form 8-K - Current report
04/1/202401:00EDGAR2Form 8-K - Current report
03/1/202408:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
19/12/202301:34EDGAR2Form DEF 14A - Other definitive proxy statements
09/12/202309:26EDGAR2Form PRE 14A - Other preliminary proxy statements
01/12/202309:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202323:40EDGAR2Form 8-K - Current report
29/11/202323:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
29/11/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
29/11/202308:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202308:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202308:45EDGAR2Form 8-K - Current report
21/11/202309:00EDGAR2Form 8-K - Current report
21/11/202308:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/11/202323:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
15/11/202311:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202323:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202323:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
14/11/202308:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202323:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
04/11/202308:00EDGAR2Form S-3 - Registration statement under Securities Act of..
04/11/202307:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202308:00EDGAR2Form DEF 14A - Other definitive proxy statements
28/10/202308:00EDGAR2Form 8-K - Current report
25/10/202308:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202322:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
21/10/202307:30EDGAR2Form PRE 14A - Other preliminary proxy statements
19/10/202322:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202322:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
03/10/202307:10EDGAR2Form 8-K - Current report
02/10/202322:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
22/8/202306:15EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202322:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/8/202322:25EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock